Boston Scientific celebrated a big milestone this week as FDA approved its Lotus Edge Valve, but how is the company handling recent regulatory headwinds?
Cardiovascular - Industry Insight
A medtech analyst says recent developments have created more uncertainty about paclitaxel-coated balloons and stents.
The San Francisco-based company and developer of the Zio Patch is set to present at the 37th Annual J.P. Morgan Healthcare Conference this week.
A recently-published meta-analysis showed higher mortality rates with Paclitaxel drug-coated balloons and drug-eluting stents, and at least two drug-eluting device trials have been paused.
Abbott Laboratories reported a strong second quarter overall, but in medical devices, the company appears to be losing share in cardiac rhythm management and neuromodulation. Could Abbott's loss in these markets be Medtronic or Boston Scientific's gain?
Cardiology societies recently updated guidelines on the management of adults at risk for sudden cardiac death to include the use of a subcutaneous implantable cardioverter-defibrillator (S-ICD). But are the latest recommendations having unintended consequences?
To kick off earnings season, one medtech analyst thinks the cardiovascular, orthopedic, and diagnostic markets grew last quarter, based on early earnings announcements.
The transcatheter aortic valve replacement market has already seen rapid growth. But the market leaders say they've only scratched the surface in terms of the growth opportunities in the space.
A recent scientific statement by the American Heart Association shines a spotlight on cardiovascular genomic testing and gives a nod to two such technologies that are currently on the market.
Boston Scientific is acquiring Apama Medical for up to $300 million, a deal that should help the company’s EP business hit its stride.
St. Jude Medical was confident that a novel cardiac device with proven outcomes would be adopted quickly, but is facing reimbursement's unrelenting brick wall.
Edwards Lifesciences is betting on a big opportunity in transcatheter mitral valve replacement, but offers up very few details on the status of its efforts in that area.
Wireless LVADs ReliantHeart is developing a fully implantable version of its HeartAssist5 LVAD.
Stroke Prevention Solutions
Solutions to Prevent Surgical Site Infections